Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$183.32 USD

183.32
350,129

-2.36 (-1.27%)

Updated Oct 7, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Research Reports for PayPal, Exxon Mobil & Goldman Sachs

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Exxon Mobil (XOM), and Goldman Sachs (GS).

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

by Ekta Bagri

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day

Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study

by Zacks Equity Research

Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.

Apple (AAPL), Biogen to Track Cognitive Health via Wearables

by Zacks Equity Research

Apple (AAPL) is collaborating with Biogen to test whether the Apple Watch and iPhone can collect and transmit biometric data on cognitive performance.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.

AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications

by Zacks Equity Research

AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.

Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.

AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study

by Zacks Equity Research

AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

by Zacks Equity Research

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies

by Zacks Equity Research

Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.

Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

by Zacks Equity Research

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?

by Zacks Equity Research

Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.

The Zacks Analyst Blog Highlights: QUALCOMM, Intuit, Boeing, Biogen and Ally Financial

by Zacks Equity Research

The Zacks Analyst Blog Highlights: QUALCOMM, Intuit, Boeing, Biogen and Ally Financial

Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel

by Zacks Equity Research

If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Sheraz Mian headshot

Top Research Reports for QUALCOMM, Intuit & Boeing

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including QUALCOMM (QCOM), Intuit (INTU) and Boeing (BA).

Ionis (IONS) Misses Estimates for Q3 Earnings and Sales

by Zacks Equity Research

Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q3 Earnings Release?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

by Zacks Equity Research

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

by Zacks Equity Research

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.